총 161건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline Antibody-mediated Rejection Biological: Clazakizumab|Drug: Normal saline Vitaeris INC|ICON Clinical Research Phase 3 2019-09-01
2 A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis Palmoplantar Pustulosis Biological: ANB019|Drug: Placebo AnaptysBio, Inc. Phase 2 2019-05-20
3 An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction Biological: Relatlimab + Nivolumab|Biological: Nivolumab|Drug: Paclitaxel|Drug: Ramucirumab Bristol-Myers Squibb Phase 2 2019-05-17
4 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Metastatic Melanoma|Squamous Cell Carcinoma of the Head and Neck|Non-small Cell Lung Cancer Biological: Lifileucel|Biological: LN-145|Drug: Pembrolizumab Iovance Biotherapeutics, Inc. Phase 2 2019-05-07
5 Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV Respiratory Syncytial Virus Infections Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A|Biological: Bexsero|Biological: Nimenrix|Biological: Menveo|Biological: Synflorix|Drug: Placebo GlaxoSmithKline Phase 1 2019-04-08
6 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-25
7 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-07
8 Tenecteplase in Stroke Patients Between 4 and 24 Hours THROMBOLYSIS Biological: Tenecteplase|Other: Placebo Genentech, Inc. Phase 3 2019-03-02
9 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients Non-Hodgkin Lymphoma Biological: Tisagenlecleucel Novartis Pharmaceuticals|Novartis Phase 2 2019-02-15
10 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Advanced Melanoma Drug: lenvatinib|Biological: pembrolizumab Merck Sharp & Dohme Corp.|Eisai Inc. Phase 2 2019-01-30